Markers Associated with Genomic Instability, Immunogenicity and Immune Therapy Responsiveness in Metaplastic Carcinoma of the Breast: Expression of γH2AX, PRPA2, P53, PD-L1 and Tumor Infiltrating Lymphocytes in 76 Cases

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Dec 12

PMID 36503417

Authors

S Voutilainen

P Heikkila

J Bartkova

H Nevanlinna

C Blomqvist

J Bartek

J Mattson

Affiliations

Soon will be listed here.

Abstract

Background: Metaplastic breast cancer (MpBC) is an aggressive subtype of breast carcinoma that is often resistant to conventional chemotherapy. Therefore, novel treatment strategies are urgently needed. Immune check point inhibitors have shown activity in programmed death-ligand 1 (PD-L1) - positive metastatic triple negative breast carcinoma (TNBC), which raises the possibility that immunotherapy may also be effective in MpBC as most of the MpBCs are triple negative. The aim of the present study was to assess genomic instability and immunogenicity in tumor specimens of patients with MpBC.

Methods: A total of 76 patients diagnosed with MpBC over a 15-year period were included in the study. We performed immunohistochemical analyses for tumor cell PD-L1, immune cell PD-L1 and p53 on tissue microarrays (TMAs), analyzed stromal and intratumoral tumor infiltrating lymphocytes (TILs) from hematoxylin and eosin-stained (H&E) slides and scored gamma-H2AX (γH2AX) and phosphorylated-RPA2 (pRPA2) from whole tissue sections. We correlated marker expression with clinicopathologic features and clinical outcome.

Results: All tumors expressed γH2AX and pRPA2 with median expressions of 43% and 44%. P53- (68%), tumor cell PD-L1- (59%) and immune cell PD-L1-positivity (62%) were common in MpBCs. Median stromal TIL and intratumoral TIL counts were 5% and 0. The spindle and squamous cell carcinomas expressed the highest levels of PD-L1 and TILs, and carcinoma with mesenchymal differentiation the lowest.

Conclusions: MpBC appears to be an immunogenic cancer with high genomic instability and frequent PD-L1-positivity, implying that check point inhibitors might be effective in MpBC. Expression levels of PD-L1 and TILs varied across different histologic subtypes, suggesting that immunotherapy might be less effective in carcinoma with mesenchymal differentiation.

References

Adams S . Dramatic response of metaplastic breast cancer to chemo-immunotherapy. NPJ Breast Cancer. 2017; 3:8. PMC: 5445614. DOI: 10.1038/s41523-017-0011-0. View

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J . Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2016; 70(3):255-259. PMC: 5339564. DOI: 10.1136/jclinpath-2016-203874. View

Afkhami M, Schmolze D, Yost S, Frankel P, Dagis A, Amanam I . Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One. 2019; 14(11):e0224726. PMC: 6834262. DOI: 10.1371/journal.pone.0224726. View

Fourtziala E, Givalos N, Alexakis N, Griniatsos J, Alevizopoulos N, Kavantzas N . Replication Protein A (RPA1, RPA2 and RPA3) expression in gastric cancer: correlation with clinicopathologic parameters and patients' survival. J BUON. 2020; 25(3):1482-1489. View

Lotfinejad P, Jafarabadi M, Shadbad M, Kazemi T, Pashazadeh F, Sandoghchian Shotorbani S . Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study. Diagnostics (Basel). 2020; 10(9). PMC: 7554852. DOI: 10.3390/diagnostics10090704. View

Maiani E, Milletti G, Nazio F, Holdgaard S, Bartkova J, Rizza S . AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature. 2021; 592(7856):799-803. PMC: 8864551. DOI: 10.1038/s41586-021-03422-5. View

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J . Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020; 382(9):810-821. DOI: 10.1056/NEJMoa1910549. View

Goodman A, Kato S, Bazhenova L, Patel S, Frampton G, Miller V . Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017; 16(11):2598-2608. PMC: 5670009. DOI: 10.1158/1535-7163.MCT-17-0386. View

10.

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T . ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30(8):1232-1243. DOI: 10.1093/annonc/mdz116. View

11.

Lien H, Lin C, Mao T, Kuo S, Hsiao C, Huang C . p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol. 2004; 204(2):131-9. DOI: 10.1002/path.1624. View

12.

Fumet J, Truntzer C, Yarchoan M, Ghiringhelli F . Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. Eur J Cancer. 2020; 131:40-50. PMC: 9473693. DOI: 10.1016/j.ejca.2020.02.038. View

13.

Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S . Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019; 38(1):268. PMC: 6585101. DOI: 10.1186/s13046-019-1266-0. View

14.

Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell D, Lu W . Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discov. 2021; 11(10):2456-2473. PMC: 8487921. DOI: 10.1158/2159-8290.CD-20-0725. View

15.

Emens L, Molinero L, Loi S, Rugo H, Schneeweiss A, Dieras V . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021; 113(8):1005-1016. PMC: 8328980. DOI: 10.1093/jnci/djab004. View

16.

Tray N, Taff J, Adams S . Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019; 79:101888. DOI: 10.1016/j.ctrv.2019.08.004. View

17.

Nagelkerke A, van Kuijk S, Sweep F, Nagtegaal I, Hoogerbrugge N, Martens J . Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol. 2011; 101(1):39-45. DOI: 10.1016/j.radonc.2011.07.009. View

18.

Stovgaard E, Dyhl-Polk A, Roslind A, Balslev E, Nielsen D . PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat. 2019; 174(3):571-584. DOI: 10.1007/s10549-019-05130-1. View

19.

Hendry S, Salgado R, Gevaert T, Russell P, John T, Thapa B . Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in.... Adv Anat Pathol. 2017; 24(5):235-251. PMC: 5564448. DOI: 10.1097/PAP.0000000000000162. View

20.

Schmid P, Rugo H, Adams S, Schneeweiss A, Barrios C, Iwata H . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 21(1):44-59. DOI: 10.1016/S1470-2045(19)30689-8. View